[
    [
        {
            "time": "2019-03-15",
            "original_text": "After Hours Most Active for Mar 15, 2019: PFE, VSTM, ZNGA, GE, CSCO, KO, WFC, DO, MSFT, BAC, INTC, HBAN",
            "features": {
                "keywords": [
                    "PFE",
                    "VSTM",
                    "ZNGA",
                    "GE",
                    "CSCO",
                    "KO",
                    "WFC",
                    "DO",
                    "MSFT",
                    "BAC",
                    "INTC",
                    "HBAN"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "finance",
                    "technology",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 3,
                "Importance": 4,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 10,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 4,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-03-15",
            "original_text": "Pharma Stock Roundup: Regulatory Updates From MRK, PFE, J&J, AGN & Others",
            "features": {
                "keywords": [
                    "MRK",
                    "PFE",
                    "J&J",
                    "AGN",
                    "Regulatory Updates"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2019-03-15",
            "original_text": "Notable ETF Inflow Detected - SPYG, PFE, BRK.B, PYPL",
            "features": {
                "keywords": [
                    "SPYG",
                    "PFE",
                    "BRK.B",
                    "PYPL",
                    "ETF Inflow"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "finance",
                    "technology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 7,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 5
            }
        },
        {
            "time": "2019-03-15",
            "original_text": "Dow 30 Stock Roundup: PFE's Herceptin Biosimilar Gets FDA Nod, VZ to Launch 5G Soon",
            "features": {
                "keywords": [
                    "PFE",
                    "Herceptin",
                    "FDA",
                    "VZ",
                    "5G"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals",
                    "telecommunications"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-03-15",
            "original_text": "The Case Against Pfizer Stock and the Rest of the Industry",
            "features": {
                "keywords": [
                    "Pfizer",
                    "Industry"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 7,
                "Sentiment": 2,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 4,
                "Source_Recency": 4
            }
        },
        {
            "time": "2019-03-15",
            "original_text": "Pisani: S&P rebalancing as some companies aggressively buy back stock",
            "features": {
                "keywords": [
                    "S&P",
                    "rebalancing",
                    "stock buyback"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "finance"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 5
            }
        }
    ]
]